Puma Biotechnology (PBYI) Return on Capital Employed (2012 - 2026)

Puma Biotechnology has reported Return on Capital Employed for 15 years, with the latest figure at 20.37% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 1117.0% year-over-year to 20.37%; the trailing twelve-month figure through Mar 2026 stood at 20.37% (down 1117.0% YoY), and the FY2025 full-year result was 27.93%, up 331.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 20.37%, down from 29.07% in the prior quarter.
• The five-year high for Return on Capital Employed was 39.56% in Q2 2025, with the low at 19.33% in Q1 2022.
• Historically, Return on Capital Employed has averaged 19.83% across 5 years, with a median of 20.68% in 2023.
• Annual changes were most pronounced in 2022 — Return on Capital Employed sank 2293 bps — and 2023, when it jumped 3724 bps.
• Puma Biotechnology's Return on Capital Employed stood at 17.84% in 2022, then soared by 55 bps to 27.74% in 2023, then retreated by 8 bps to 25.61% in 2024, then grew by 13 bps to 29.07% in 2025, then fell by 30 bps to 20.37% in 2026.
• The last three Return on Capital Employed figures came in at 20.37% (Q1 2026), 29.07% (Q4 2025), and 28.89% (Q3 2025), per Business Quant data.